Pfizer Likes Consumer Business Right Where It Is, Or Eventually Could Be
This article was originally published in The Tan Sheet
Driven by US sales of Nexium 24HR and Advil, Pfizer's fiscal 2016 first-quarter consumer product revenues increased 2% to $822m. CEO Ian Read says Pfizer is open to adding to or selling off its consumer business, but currently likes it just where it is.
Register for our free email digests: